Through advancements in science and robotics, we’ve expanded testing capabilities, providing same-day, precise results at a cost conducive to frequent testing.
This integration allows us to significantly impact our nation’s schools, government entities, hospitals, and businesses, not only in addressing the current pandemic but also in meeting future diagnostic testing demands effectively.
HEALTHQUEST employs a real-time RT-PCR molecular test for detecting the SARS-CoV-2 virus responsible for COVID-19 respiratory syndrome. Additionally, this test is engineered to differentiate and exclude Influenza and Respiratory Syncytial Virus, both of which share common symptoms with COVID-19.
The Healthquest SARS-CoV-2 Molecular Assay employs real-time RT-PCR technology to qualitatively detect nucleic acid from SARS-CoV-2 in respiratory specimens from both upper and lower respiratory tracts. PCR (polymerase chain reaction) is a technique used to amplify short sequences of DNA or RNA, even in samples with minimal genetic material. It efficiently replicates selected DNA or RNA sections, generating numerous copies. Positive results indicate the presence of SARS-CoV-2 RNA; however, patient infection status should be determined by considering clinical history and other diagnostic information. Positive results do not exclude bacterial infection or co-infection with other viruses, and the detected agent may not be the sole cause of disease.
By rapidly expanding capacity, acquiring instrumentation, equipment, and staff, Healthquest aims to meet the unprecedented demand for testing. This initiative will enable Healthquest to conduct up to 10,000 tests per day with results available within 24 hours.
The Healthquest serology test detects antibodies indicating a previous immune response to COVID-19 (also known as coronavirus or SARS-CoV-2). A positive result from this IgG antibody test suggests prior exposure to COVID-19 and antibody development within the body. Although it may take up to 14 days after symptom onset for antibodies to emerge, approximately 91% of individuals produce them within 8-13 days. Some COVID-19 cases are asymptomatic yet display detectable antibody responses. While there’s speculation that antibodies may confer immunity to future infections, conclusive data is lacking. These tests provide insight into disease prevalence by identifying individuals with antibody development within the population.
